Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Slides:

Advertisements

Similar presentations

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

Advertisements

Echocardiography view

Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Serial imaging while on immunosuppressive therapy (two subjects).

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Survival without tracheostomy

Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Bland–Altman plot of slopes of measurement 1 versus 2

Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

a–h) Examples of short frenula in children and teenagers.

In vitro quantification of exon skipping associated with 15 premature termination codons using minigenes. In vitro quantification of exon skipping associated.

Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A white elephant or the elephant in the room

The linear interpolation analysis and the fitting-curve analysis give lower values for lung clearance index (LCI). a) Bland–Altman plots of the absolute.

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Agreement regarding tidal breathing parameters between VoluSense Pediatrics (VSP) (VoluSense, Bergen, Norway) and Exhalyzer D (Exhal.D) (Eco Medics, Duernten,

The variability of probability of that the length of stay is longer than the median by country. The variability of probability of that the length of stay.

A) The flexible 1.9 mm diameter and 900 mm length cryoprobe, b) connected to the cryotherapy equipment. c) Marks on the distal area of the probe (1 cm.

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Portions of two representative reports, a, c and e) one during noninvasive ventilation through a helmet and b, d and f) the other through mask. Portions.

Intensity of statistical methods and reporting subdivided by the journal groups. Intensity of statistical methods and reporting subdivided by the journal.

Concentration of inflammatory cytokines in epithelial lining fluid (ELF) were plotted for the normal control, smoker normal forced oscillation technique.

Average mean arterial pressure (Pa) during lung volume recruitment (LVR) in (a) the respiratory muscle weakness (RMW) group and (b) the control group.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

a) Mortality per time point (p<0

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Patients' and partners' experience of anxiety in the Netherlands (NL) and Germany (GE), based on the Generalised Anxiety Disorder-single item questionnaire.

The regression lines between the asynchrony index (AI) and the double true index (DTI) shown for overall data, and for mask and helmet separately. The.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Α1-Antitrypsin (AAT) therapy considerations: a) practical difficulties with AAT infusions; b) concerns regarding AAT doses >60 mg·kg−1 per week. α1-Antitrypsin.

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Diagram of rebreathe apparatus.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. #: time-points were statistically.

A–d) Bland–Altman plots of absolute differences between tremoFlo at 5 and 7 Hz versus the mean of the two measurements in resistance R and reactance X.

Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation in year 1 and year 2 (full cohort, year 1 or year 2). a)

Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

Bland–Altman plots for (A) interobserver and (B) test-retest reliability, with difference between measurements (y axis) plotted against mean of the measurements.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)

Presentation transcript:

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Mean of projected apnoea threshold (pAT) on the x-axis in L·min−1·kPa−1 and the difference between pAT on the y-axis in L·min−1·kPa−1. The mean pAT is ∼0.3 kPa in both methods. The limits of agreement of pAT-R are ∼1.5 kPa and of pAT-SS are ∼2.5 kPa. There is no trend in the mean projected apnoea threshold. Denise C. Mannée et al. ERJ Open Res 2018;4:00141-2017 ©2018 by European Respiratory Society